Our Products and Product Candidates
The following table summarizes key information on our portfolio of lead products and product candidates as of the date of this Annual Report.
- Neurology
- Nephrology and Hematology
- Endocrinology
- Rheumatology
- undisclosed
- Program
- Preclinical
- Phase 1
- Proof of Concept
- Registrational
- Commercial
Generalized Myasthenia Gravis (gmG)
Primary Immune Thrombocytopenia (ITP)
Generalized Myasthenia Gravis (gMG)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Seronegative gMG
Ocular MG (oMG)
Primary Immune Thrombocytopenia (ITP)
Graves' Disease
Myositis (IMNM, ASyS, DM)
Sjogren's Disease
Systemic Sclerosis
Antibody Mediated Rejection (AMR)
Multifocal Motor Neuropathy (MMN)
Delayed Graft Function (DGF)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Congenital Myasthenic Syndromes (CMS)
Spinal Muscular Atrophy (SMA)
Undisclosed
IgA Nephropathy
Undisclosed
Undisclosed
Undisclosed
Undisclosed
Undisclosed